Amyotrophic lateral sclerosis: recent advances and future therapies

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Current Opinion in Neurology

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.wco.0000187248.21103.c5PMID 16280684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amino acids for amyotrophic lateral sclerosis / motor neuron disease.

  2008cited by this paper
• The complex genetics of amyotrophic lateral sclerosis.

  2007cited by this paper
• Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease.

  2007cited by this paper
• Virus‐delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis

  2005cited by this paper
• Synergy of insulin‐like growth factor‐1 and exercise in amyotrophic lateral sclerosis

  2005cited by this paper
• The therapeutic potential of RNA interference

  2005cited by this paper
• Elevation of the Hsp70 chaperone does not effect toxicity in mouse models of familial amyotrophic lateral sclerosis

  2005cited by this paper
• Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS

  2005cited by this paper
• Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis

  2005cited by this paper
• Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice

  2005cited by this paper
• GDNF Delivery Using Human Neural Progenitor Cells in a Rat Model of ALS

  2005cited by this paper
• Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model

  2005cited by this paper
• Molecular and cellular pathways of neurodegeneration in motor neurone disease

  2005cited by this paper
• Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS

  2005cited by this paper
• Specification of motoneurons from human embryonic stem cells

  2005cited by this paper
• β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression

  2005cited by this paper
• Therapeutic gene silencing in neurological disorders, using interfering RNA

  2005cited by this paper
• Modulation of neurodegeneration by molecular chaperones

  2005cited by this paper
• Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model

  2005cited by this paper
• Patient-specific embryonic stem cells derived from human SCNT blastocysts.

  2005cited by this paper
• Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

  2004cited by this paper
• Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial

  2004cited by this paper
• Effects of high‐intensity endurance exercise training in the G93A mouse model of amyotrophic lateral sclerosis

  2004cited by this paper
• Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice

  2004cited by this paper
• Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid

  2004cited by this paper
• Protein aggregation and neurodegenerative disease

  2004cited by this paper
• Current pharmacological management of amyotropic lateral sclerosis and a role for rational polypharmacy

  2004cited by this paper
• VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model

  2004cited by this paper
• A novel action of histone deacetylase inhibitors in a protein aggresome disease model.

  2004cited by this paper
• Lessons from models of SOD1-linked familial ALS.

  2004cited by this paper
• Cannabinoids and neuroinflammation

  2004cited by this paper
• Celastrols as Inducers of the Heat Shock Response and Cytoprotection*[boxs]

  2004cited by this paper
• The promise of minocycline in neurology.

  2004cited by this paper
• A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis.

  2004cited by this paper
• Unraveling the mechanisms involved in motor neuron degeneration in ALS.

  2004cited by this paper
• Complex genetics of amyotrophic lateral sclerosis.

  2004cited by this paper
• Clinical potential of minocycline for neurodegenerative disorders.

  2004cited by this paper
• Multi‐drug therapy in amyotrophic lateral sclerosis: The case for a multi‐drug approach

  2004cited by this paper
• DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4).

  2004cited by this paper
• A clinical trial of creatine in ALS

  2004cited by this paper
• Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis

  2004cited by this paper
• Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans

  2003cited by this paper
• A randomized sequential trial of creatine in amyotrophic lateral sclerosis

  2003cited by this paper
• A double‐blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched‐chain amino acid levels and clinical parameters

  2003cited by this paper
• VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death

  2003cited by this paper
• Paradigms for the identification of new genes in motor neuron degeneration

  2003cited by this paper
• A therapeutic role for cyclooxygenase‐2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis

  2003cited by this paper
• Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice

  2003cited by this paper
• Intravenous Administration of Human Umbilical Cord Blood Cells in a Mouse Model of Amyotrophic Lateral Sclerosis: Distribution, Migration, and Differentiation

  2003cited by this paper
• Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

  2003cited by this paper
• Efficient three‐drug cocktail for disease induced by mutant superoxide dismutase

  2003cited by this paper
• Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis

  2003cited by this paper
• A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

  2003cited by this paper
• Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model

  2003cited by this paper
• Riluzole for ALS: what is the evidence?

  2003cited by this paper
• Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis

  2003cited by this paper
• Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS

  2003cited by this paper
• Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis

  2002cited by this paper
• Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)

  2002cited by this paper
• Inflammatory processes in amyotrophic lateral sclerosis

  2002cited by this paper
• Accumulation of SOD1 Mutants in Postnatal Motoneurons Does Not Cause Motoneuron Pathology or Motoneuron Disease

  2002cited by this paper
• Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis.

  2002cited by this paper
• Toxic Proteins in Neurodegenerative Disease

  2002cited by this paper
• Minocycline delays disease onset and mortality in a transgenic model of ALS

  2002cited by this paper
• Neuroprotective Effects of Glial Cell Line-Derived Neurotrophic Factor Mediated by an Adeno-Associated Virus Vector in a Transgenic Animal Model of Amyotrophic Lateral Sclerosis

  2002cited by this paper
• Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

  2002cited by this paper
• Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells.

  2002cited by this paper
• Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS

  2002cited by this paper
• Human Intrathecal Transplantation of Peripheral Blood Stem Cells in Amyotrophic Lateral Sclerosis

  2001cited by this paper
• Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome 2q33-q34: candidate genes for ALS2.

  2001cited by this paper
• Rats Expressing Human Cytosolic Copper–Zinc Superoxide Dismutase Transgenes with Amyotrophic Lateral Sclerosis: Associated Mutations Develop Motor Neuron Disease

  2001cited by this paper
• The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis

  2001cited by this paper
• Anomalous anatomy of speech–language areas in adults with persistent developmental stuttering

  2001cited by this paper
• Neuron-Specific Expression of Mutant Superoxide Dismutase 1 in Transgenic Mice Does Not Lead to Motor Impairment

  2001cited by this paper
• Increased expression of the pro‐inflammatory enzyme cyclooxygenase‐2 in amyotrophic lateral sclerosis

  2001cited by this paper
• Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity.

  2001cited by this paper
• Activate your online subscription

  2001cited by this paper
• Cytokine Effects on Glutamate Uptake by Human Astrocytes

  2000cited by this paper
• Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement?

  2000cited by this paper
• A controlled trial of recombinant methionyl human BDNF in ALS

  1999cited by this paper
• Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

  1998cited by this paper
• A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.

  1998cited by this paper
• Prostaglandins stimulate calcium-dependent glutamate release in astrocytes

  1998cited by this paper
• A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

  1998cited by this paper
• Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.

  1997cited by this paper
• Effect of recombinant human insulin-like growth factor-I on progression of ALS

  1997cited by this paper
• The pharmacology and mechanism of action of riluzole

  1996cited by this paper
• A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.

  1996cited by this paper
• Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.

  1996cited by this paper
• Controlled trial of nimodipine in amyotrophic lateral sclerosis.

  1996cited by this paper
• Dose-ranging study of riluzole in amyotrophic lateral sclerosis

  1996cited by this paper
• A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis

  1996cited by this paper
• A double‐blind placebo‐controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis

  1996cited by this paper
• A clinical trial of verapamil in amyotrophic lateral sclerosis

  1996cited by this paper
• Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis.

  1995cited by this paper
• An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria.

  1995cited by this paper
• Pharmacological modulation of heat shock factor 1 by antiinflammatory drugs results in protection against stress-induced cellular damage.

  1995cited by this paper
• Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.

  1994cited by this paper
• A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

  1994cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

  1993cited by this paper

• Riluzole partially restores RNA polymerase III complex assembly in cells expressing the leukodystrophy-causative variant POLR3B R103H

  2022cites this paper
• Serotonin and basal sensory–motor control

  2020cites this paper
• Protein Carbonylation in Brains of Subjects with Selected Neurodegenerative Disorders

  2017cites this paper
• Antidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models

  2017cites this paper
• Role of ROS and RNS Sources in Physiological and Pathological Conditions

  2016cites this paper
• Serotonin and conditioning: focus on Pavlovian psychostimulant drug conditioning.

  2015cites this paper
• Chapter 10 – Role of Oxidative Stress in Neurodegenerative Diseases and Other Diseases Related to Aging

  2014cites this paper
• The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.

  2014cites this paper
• Clinical relevance of stem cell therapies in amyotrophic lateral sclerosis.

  2014cites this paper
• Amino acids as biomarkers in the SOD1(G93A) mouse model of ALS.

  2014cites this paper
• Reduction in hSOD1 copy number significantly impacts ALS phenotype presentation in G37R (line 29) mice: implications for the assessment of putative therapeutic agents

  2014cites this paper
• Questions regarding the predictive value of one evolved complex adaptive system for a second: exemplified by the SOD1 mouse.

  2013cites this paper
• Altered expression of DJ-1 and PINK1 in sporadic ALS and in the SOD1(G93A) ALS mouse model.

  2013cites this paper
• Management of Amyotrophic Lateral Sclerosis

  2012cites this paper
• A Case of Amyotrophic Lateral Sclerosis complicated with Idiopathic Thrombocytopenic Purpura

  2012cites this paper
• Minocycline Down-Regulates Topical Mucosal Inflammation during the Application of Microbicide Candidates

  2012cites this paper
• Cause of Death in Japanese Patients with Amyotrophic Lateral Sclerosis on Tracheostomy-Positive Pressure Ventilation

  2012cites this paper
• Molecular mechanism involved in Amyotrophic Lateral Sclerosis: role of Bcl2-A1 and TDP-43 genes in motor neuron degeneration

  2012cites this paper
• Dendritic changes in visual pathways in glaucoma and other neurodegenerative conditions.

  2011cites this paper
• Vascular Endothelial Growth Factor Attenuates Neurodegenerative Changes in the NSC-34 Motor Neuron Cell Line Induced by Cerebrospinal Fluid of Sporadic Amyotrophic Lateral Sclerosis Patients

  2011cites this paper
• Extraction of biomedical traits for patients with Amyotrophic Lateral Sclerosis using parallel and hierarchical classifiers

  2011cites this paper
• Towards a multimodal treatment of depression: a minireview on the potential role of antibiotics.

  2011cites this paper
• Autoimmunity in Amyotrophic Lateral Sclerosis: Past and Present

  2011cites this paper
• Characterization of dendritic changes induced by elevated intraocular pressure in a chronic glaucoma model

  2011cites this paper
• Lipid peroxidation and neurodegenerative disease.

  2011cites this paper
• Autologous Bone M arrow Derived Stem Cells for M otor Neuron Disease with Anterior Horn Cell Involvem ent

  2011cites this paper
• The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis.

  2010cites this paper
• Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3β phosphorylation

  2010cites this paper
• Neuroprotective Drug Riluzole Amplifies the Heat Shock Factor 1 (HSF1)- and Glutamate Transporter 1 (GLT1)-dependent Cytoprotective Mechanisms for Neuronal Survival*

  2010cites this paper
• Moderate exercise delays the motor performance decline in a transgenic model of ALS.

  2010cites this paper
• Cytopathological Mechanisms in Mitochondrial Disease

  2010cites this paper
• Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis

  2010cites this paper
• Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities

  2010cites this paper
• Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis.

  2009cites this paper
• Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration.

  2009cites this paper
• Stratifying disease stages with different progression rates determined by electrophysiological tests in patients with amyotrophic lateral sclerosis

  2009cites this paper
• Adaptation to G93Asuperoxide dismutase 1 in a motor neuron cell line model of amyotrophic lateral sclerosis

  2009cites this paper
• Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up.

  2009cites this paper
• Proteomic analysis of plasma from Portuguese patients with familial amyotrophic lateral sclerosis

  2008cites this paper
• Altered lipid metabolism in brain injury and disorders.

  2008cites this paper
• Cause of death and clinical grading criteria in a cohort of amyotrophic lateral sclerosis cases undergoing autopsy from the Scottish Motor Neurone Disease Register

  2008cites this paper
• The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development.

  2008cites this paper
• Design, power, and interpretation of studies in the standard murine model of ALS

  2008cites this paper
• Riluzole Increases the Amount of Latent HSF1 for an Amplified Heat Shock Response and Cytoprotection

  2008cites this paper
• Nörolojik Hastalıklarda Kök Hücre Tedavileri

  2008cites this paper
• Heat Shock Proteins and Protection of the Nervous System

  2007cites this paper
• Role of Lipids in Brain Injury and Diseases.

  2007cites this paper
• Early necrosis and apoptosis of Schwann cells transplanted into the injured rat spinal cord

  2007cites this paper
• An update on pharmacological approaches to neurodegenerative diseases

  2007cites this paper
• Validation Using a Mathematical Model Method for Counting Motor Units in Mice and

  2007cites this paper
• Genetic Characterisation of Neurodegenerative disorders

  2007cites this paper
• The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis.

  2007cites this paper
• The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.

  2007cites this paper
• Adult Olfactory Bulb Neural Precursor Cell Grafts Provide Temporary Protection From Motor Neuron Degeneration, Improve Motor Function, and Extend Survival in Amyotrophic Lateral Sclerosis Mice

  2007cites this paper
• Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS.

  2007cites this paper
• Method for counting motor units in mice and validation using a mathematical model.

  2007cites this paper
• SEROTONERGIC MECHANISMS IN AMYOTROPHIC LATERAL SCLEROSIS

  2006cites this paper
• Does VEGF represent a potential treatment for amyotrophic lateral sclerosis?

  2006cites this paper
• Role of inflammation and cellular stress in brain injury and central nervous system diseases

  2006cites this paper
• AEOL-10150 (Aeolus).

  2006cites this paper
• Digital Commons @ East Tennessee State University Digital Commons @ East Tennessee State University

  year unknowncites this paper